Analysts predict that Rubius Therapeutics Inc (NASDAQ:RUBY) will report earnings per share of ($0.44) for the current quarter, Zacks reports. Zero analysts have made estimates for Rubius Therapeutics’ earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.55). Rubius Therapeutics posted earnings of ($3.33) per share in the same quarter last year, which would suggest a positive year over year growth rate of 86.8%. The business is expected to issue its next quarterly earnings results on Friday, August 30th.

On average, analysts expect that Rubius Therapeutics will report full year earnings of ($1.80) per share for the current fiscal year, with EPS estimates ranging from ($2.26) to ($1.13). For the next fiscal year, analysts forecast that the firm will post earnings of ($2.13) per share, with EPS estimates ranging from ($2.48) to ($1.19). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Rubius Therapeutics.

Rubius Therapeutics (NASDAQ:RUBY) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.42) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.04).

Separately, Zacks Investment Research lowered shares of Rubius Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 30th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Rubius Therapeutics has an average rating of “Buy” and a consensus price target of $30.00.

Shares of RUBY stock traded up $0.56 during trading hours on Friday, hitting $16.83. 1,748 shares of the company were exchanged, compared to its average volume of 298,507. The company has a quick ratio of 18.64, a current ratio of 18.64 and a debt-to-equity ratio of 0.13. Rubius Therapeutics has a 52-week low of $12.70 and a 52-week high of $33.01. The firm has a market cap of $1.34 billion and a P/E ratio of -7.34.

In other news, Director Robert Langer sold 7,500 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $17.57, for a total transaction of $131,775.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Christopher L. Carpenter sold 48,000 shares of the stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $15.84, for a total transaction of $760,320.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 70,196 shares of company stock valued at $1,186,015. 58.40% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of RUBY. Legal & General Group Plc purchased a new stake in shares of Rubius Therapeutics during the third quarter worth approximately $44,000. New York State Common Retirement Fund purchased a new position in Rubius Therapeutics in the fourth quarter valued at approximately $116,000. Metropolitan Life Insurance Co. NY grew its position in shares of Rubius Therapeutics by 320.5% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,191 shares of the company’s stock worth $116,000 after acquiring an additional 5,481 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Rubius Therapeutics during the first quarter worth approximately $117,000. Finally, BNP Paribas Arbitrage SA grew its position in shares of Rubius Therapeutics by 19,092.3% during the first quarter. BNP Paribas Arbitrage SA now owns 7,485 shares of the company’s stock worth $135,000 after acquiring an additional 7,446 shares during the last quarter. 91.33% of the stock is currently owned by institutional investors and hedge funds.

Rubius Therapeutics Company Profile

Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.

Further Reading: Buy-Side Analysts

Get a free copy of the Zacks research report on Rubius Therapeutics (RUBY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Rubius Therapeutics (NASDAQ:RUBY)

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.